Tumor Ablation Market Size Worth USD 5.22 Billion by 2034 | CAGR: 11.4%

​​​​​​The global tumor ablation market size is expected to reach USD 5.22 billion by 2034, according to a new study by Polaris Market Research. The report “Tumor Ablation Market Share, Size, Trends, Industry Analysis Report: By Technology (Radiofrequency (RF) Ablation, Microwave Ablation, Cryoablation, and Others), Mode of Treatment, Application, and Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Technical advancements, mainly in robotics-assisted tumor ablation techniques, are a significant driver in the tumor ablation market. Robotics systems, equipped with navigation capabilities and advanced imaging, enable surgeons to remove cancerous tissue and accurately target with less damage to healthy cells. Microwave ablation (MWA) is the latest technology that eliminates tumors by using microwave energy to generate heat. The surgeon inserts an open incision or a tiny laparoscopic port to access the tumor by using the technology. An ultrasonic guidance or a CT scanner is utilized to identify the exact location of the tumor in the body. A thin antenna that radiates microwaves is then inserted into the tumor. The probe delivers intense heat that kills tumor tissue, predominantly within 10 minutes.

Key strategies adopted by major players to enhance their product portfolios, such as collaborations and partnerships, are expected to positively impact the tumor ablation market. Terumo Europe and University Medical Center Utrecht (UMC Utrecht), for instance, signed a Memorandum of Understanding (MoU) in July 2021 to further strengthen their longstanding partnership in oncology, focusing on chemoembolization and tumor ablation through technological innovations.

The rising incidence of lung cancer, fueled by the expansion of unhealthy habits and a surge in research and development endeavors associated with product launches, is driving the growth of the market. According to the 2025 statistics from the American Cancer Society, an estimated 226,650 new cases of lung cancer were expected to be diagnosed in the U.S. This increased prevalence is anticipated to drive demand for tumor ablation devices, thereby contributing to market growth throughout the forecast period.

The growing importance of image-guided ablation techniques enables targeted tumor treatment while minimizing damage to surrounding healthy tissue. Also, there's a rising adoption of radiofrequency and microwave ablation technologies, delivering efficient and effective treatment options. The tumor ablation market is witnessing an increase in demand for minimally invasive techniques owing to their associated benefits, like shorter recovery times and reduced complications. Continuous research and development efforts are driving innovations in ablation devices and techniques, contributing to the market's overall growth.

A few of the global key market players include AngioDynamics Inc., Boston Scientific Corp., BVM Medical Ltd., BTG International Ltd., EDAP TMS S.A., Integra LifeSciences Holdings Corp., Medtronic plc., Mermaid Medical, SonaCare Medical LLC, and St. Jude Medical Inc.

Tumor Ablation Market Report Highlights

• In 2025, the radiofrequency ablation segment accounted for the largest revenue share in the market. The precision and safety of radiofrequency ablation make it a significant choice for both physicians and patients.
• The lung cancer segment is growing at the fastest rate. This is because smoking is the leading cause of lung cancer and accounts for the majority of cases.
• In 2025, North America accounted for the largest market share. Several key factors, including government support for robust healthcare, high purchasing power, accessible reimbursement, and rising cancer incidence, are driving this region's growth.
• The Asia Pacific is expected to witness the fastest market growth. This is due to the rising aging population having various chronic illnesses, such as cancer and diabetes. Moreover, the expanding market, with a surge in companies and substantial investments by major manufacturers in product research and development, is projected to drive regional market growth.

Request a free sample copy or read the full market insights :  tumor ablation market Report

Where is the Tumor Ablation Market Headed?

Our recent report on the tumor ablation industry reveals that the rising use of artificial intelligence (AI), imaging, and robotics technologies for precision ablation will create lucrative opportunities during the forecast period. In addition, providers are tailoring ablation treatments to individual health status, such as age, tumor type, and comorbidities. This approach improves acceptability, especially for older or high-risk patients. Thus, increasing emphasis on personalized treatments will boost the industry growth in the coming years.

What Does the Tumor Ablation Report Reveal?

• What is the global market size, opportunities, emerging trends, and CAGR for the market from 2025 to 2034?
• Which factors are responsible for the industry expansion?
• Who are the key industry players? What is their relative position in terms of competitive positioning?
• How do different technologies, such as radiofrequency (RF) ablation, microwave ablation, cryoablation, and others, influence the market landscape?
• How does the market differ in terms of technology, mode of treatment, application, and geography? Which is the leading application?
• What are the opportunities in different regional markets, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?

Polaris Market Research has segmented the tumor ablation market report based on technology, mode of treatment, application, and region:

By Technology Outlook (Revenue – USD Billion, 2021–2034)

• Radiofrequency (RF) Ablation
• Microwave Ablation
• Cryoablation
• Others

By Mode of Treatment Outlook (Revenue – USD Billion, 2021–2034)

• Surgical Ablation
• Laparoscopic Ablation
• Percutaneous Ablation

By Application Outlook (Revenue – USD Billion, 2021–2034)

• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Bone Metastasis
• Others

By Regional Outlook (Revenue – USD Billion, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America